Related Experiment Video
Updated: Jan 24, 2026

Ex Vivo Infection of Human Lymphoid Tissue and Female Genital Mucosa with Human Immunodeficiency Virus 1 and Histoculture
Published on: October 12, 2018
Neurocognitive Development in Perinatally Human Immunodeficiency Virus-infected Adolescents on Long-term Treatment,
Malon Van den Hof1, Anne Marleen Ter Haar1, Henriette J Scherpbier1
1Pediatric Infectious Diseases, University of Amsterdam, The Netherlands.
Insights
Perinatally HIV-infected adolescents on combination antiretroviral therapy (cART) showed similar cognitive development to HIV-negative peers over time. However, executive functioning declined more in the HIV-positive group, possibly due to earlier brain damage.
Area of Science:
- Neuroscience
- Pediatrics
- Infectious Diseases
Background:
- Perinatally human immunodeficiency virus (HIV)-infected adolescents on combination antiretroviral therapy (cART) may experience cognitive impairment.
- Previous cross-sectional studies indicated significant cognitive differences between HIV-positive (PHIV+) and HIV-negative (HIV-) adolescents.
Purpose of the Study:
- To longitudinally compare cognitive development trajectories in PHIV+ adolescents receiving cART versus HIV-negative controls.
- To identify factors influencing cognitive changes over time in this cohort.
Main Methods:
- A longitudinal study repeating cognitive assessments after a mean of 4.6 years in PHIV+ and HIV- adolescents.
- Linear mixed models were used to compare cognitive trajectories in intelligence quotient (IQ), processing speed, working memory, executive functioning, learning, and visual-motor function.
- Multivariate normative comparison (MNC) assessed the prevalence of cognitive impairment.
Main Results:
- While IQ scores increased more in PHIV+ participants, their executive functioning significantly decreased compared to HIV- controls.
- Significant differences in executive functioning emerged over time between the groups.
- No significant differences in trajectories for processing speed, working memory, learning, or visual-motor function were observed.
Conclusions:
- cART-treated PHIV+ adolescents exhibit comparable global cognitive development to HIV-negative peers over time.
- A diverging trajectory in executive functioning among PHIV+ adolescents suggests potential long-term effects, possibly linked to earlier neurological impact of HIV.
Background:
A cross-sectional analysis of the Neurological, cOgnitive and VIsual performance in hiv-infected Children cohort showed significant cognitive impairment in combination antiretroviral therapy (cART)-treated, perinatally human immunodeficiency virus (HIV)-infected adolescents (PHIV+) compared to age-, sex-, ethnicity- and socioeconomic status (SES)-matched HIV-negative controls (HIV-). In this longitudinal study, we compared cognitive development in the same adolescents over time.
Methods:
We repeated the standardized cognitive test battery after a mean of 4.6 years (standard deviation 0.3). In participants who completed both assessments, we compared cognitive trajectories between groups in the domains of intelligence quotient (IQ), processing speed, working memory, executive functioning, learning ability, and visual-motor function, using linear mixed models. We explored associations with disease- and treatment-related factors and used multivariate normative comparison (MNC) to determine the prevalence of cognitive impairment.
Results:
There were 21 PHIV+ and 23 HIV- participants that completed 2 assessments and were similar concerning age, sex, ethnicity, and SES. Compared to HIV- participants, in PHIV+ participants the IQ score increased significantly more over time (group*time 6.01, 95% confidence interval [CI] 1.5-10.50; P = .012), whereas executive functioning decreased significantly more (group*time -1.43 z score, 95% CI -2.12 to -0.75; P < .001), resulting in the disappearance and appearance of significant differences. Processing speed, working memory, learning ability, and visual-motor function trajectories were not statistically different between groups. Univariately, those who had started cART at an older age deviated more in executive functioning (-0.13 z score, 95% CI -0.24 to -0.02; P = .043). The prevalence of cognitive impairments by MNC was similar in both groups, at both time points.
Conclusions:
The cART-treated PHIV+ adolescents appeared to have similar global cognitive development, compared to their healthy peers. Executive functioning trajectory appears to deviate, potentially explained by earlier brain damage.
Related Concept Videos
Cognitive Development During Adolescence
Longitudinal Research
Longitudinal Studies
Erikson's Theory on Socioemotional Development during Adolescence
Sign Test for Matched Pairs
To conduct the sign test, we first calculate the differences in...
Bioavailability Study Design: Healthy Subjects Versus Patients

